EU Approves Midostaurin for AML, Advanced Systemic Mastocytosis

September 20, 2017 – The European Commission has approved midostaurin for adults with newly diagnosed FLT3-positive acute myeloid leukemia (AML) and advanced systemic mastocytosis (SM), including aggressive systemic mastocytosis (SM), SM with associated hematological neoplasm (SM-AHN), and mast cell leukemia. Midostaurin is approved for AML in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation … (leggi tutto)